Incannex Healthcare Limited (IXHL)

NASDAQ: IXHL · IEX Real-Time Price · USD
2.98
-0.28 (-8.74%)
At close: Dec 7, 2022 3:57 PM
3.40
+0.42 (14.29%)
After-hours: Dec 7, 2022 7:31 PM EST
-8.74%
Market Cap 198.68M
Revenue (ttm) 788,654
Net Income (ttm) -14.90M
Shares Out 1.21B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,485
Open 3.41
Previous Close 3.26
Day's Range 2.98 - 3.45
52-Week Range 2.98 - 96.07
Beta 1.78
Analysts n/a
Price Target n/a
Earnings Date n/a

About IXHL

Since 2019, Incannex Healthcare has been conducting research and development for synthetic cannabidiol pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. Our mission is to create first-in-class pharmaceutical drugs and therapies for patients that we believe have unmet medical needs. In particular, we are developing three unique pharmaceutical compositions to target five indications: obstructive sleep apnea, traumatic brain injury/concussion, rheumatoid arthritis, inflammatory bowel disease and in... [Read more]

Industry Drug Manufacturers-Specialty & Generic
Founded 2001
CEO Joel Latham
Employees 4
Stock Exchange NASDAQ
Ticker Symbol IXHL
Full Company Profile

Financial Performance

In 2022, IXHL's revenue was 788,654, a decrease of -60.03% compared to the previous year's 1.97 million. Losses were -14.90 million, 31.0% more than in 2021.

Financial numbers in AUD Financial Statements

News

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

MELBOURNE, Australia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing medicinal ...

1 week ago - GlobeNewsWire

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

MELBOURNE, Australia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing medicinal ...

1 week ago - GlobeNewsWire

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

MELBOURNE, Australia, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex' or the ‘Company'), is please...

1 month ago - GlobeNewsWire

Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference

MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid ph...

2 months ago - GlobeNewsWire

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Highlights: Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A Engagement of Curia follows achievement of "proof-of-concept" formulation development A patent has been filed...

4 months ago - PRNewsWire

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20, 2022 The trial will be performed at CMAX Clini...

4 months ago - PRNewsWire

Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference

MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medici...

5 months ago - PRNewsWire

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of ...

Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited superior safety and efficacy metrics to mid and h...

6 months ago - PRNewsWire

Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea

MELBOURNE, Australia , May 17, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicin...

6 months ago - PRNewsWire

Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC

MELBOURNE, Australia , May 12, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicin...

6 months ago - PRNewsWire

Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly...

Highlights: The study compared IHL-216A to its component drugs, cannabidiol (CBD) and isoflurane, in a model developed in collaboration with the US National Football League (NFL) IHL-216A restored spati...

6 months ago - PRNewsWire

Quarterly Activities Report and Appendix 4C Cash Flow Statement

Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial p...

7 months ago - PRNewsWire

Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M

MELBOURNE, Australia , April 28, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medic...

7 months ago - PRNewsWire

Incannex Healthcare rallies after airing plan to buy cannabis medicine company APIRx

Incannex Healthcare Ltd. IXHL, -4.23% shares jumped 7% after the Australia-based cannabinoid and psychedelic compound medicine development company said it would pay $93.3 million to acquire APIRx Pharma...

8 months ago - Market Watch

Incannex to Acquire APIRx Pharmaceuticals USA, LLC

Highlights: APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain, dementia, Parkinson's disease, restless leg...

8 months ago - PRNewsWire

Why Incannex Healthcare Stock Crashed Today

Profit-taking after a big gain earlier this week took its toll.

8 months ago - The Motley Fool

Starbucks to phase out iconic cups, AMC rises after buying major Hycroft stake, Incannex rallies

Yahoo Finance Live takes a look at several of the day's trending stock tickers, including Volvo's partnership with Starbucks to install EV charging stations.

Other symbols: AMCHYMCSBUX
8 months ago - Yahoo Finance

IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too

Here's what investors intrigued by today's 100% rise in Incannex Healthcare and IXHL stock may want to know about this company. The post IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrock...

8 months ago - InvestorPlace

What's Going On With Incannex Healthcare's Stock Today?

Incannex Healthcare Ltd (NASDAQ: IXHL) is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clin...

8 months ago - Benzinga

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients...

MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- Highlights: 20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment compar...

8 months ago - PRNewsWire

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality a...

MELBOURNE, Australia, March 3, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicin...

9 months ago - PRNewsWire

Incannex Completes Listing of American Depositary Shares on Nasdaq; Rings Nasdaq Closing Bell

MELBOURNE, Australia, Feb. 28, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicin...

9 months ago - PRNewsWire